Postoperative ileus is a common complication and can be associated with prolonged hospital stay. Alvimopan, a µ-opioid receptor antagonist, has been shown to reduce the duration of postoperative ileus ...
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Mar 12, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced ...
Am J Health Syst Pharm. 2007;64(20):S13-S20. The use of alvimopan for the treatment of OBD was explored in several Phase II and Phase III studies. One Phase III randomized, placebo-controlled study ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract does not include a full text component. If you have the ...
The postoperative ileus market is expected to witness steady growth driven by the rising volume of abdominal and gastrointestinal surgeries worldwide. Increasing awareness of enhanced recovery ...
(HealthDay News) — A noninvasive, abdominal acoustic monitoring device can distinguish postoperative ileus (POI) from patients and controls without POI, according to a proof-of-concept study published ...
Postoperative ileus complicates the recovery from intestinal surgery with a great economic burden. How this morbid condition spreads throughout the entire gut remains unknown, but new findings show ...
Comparative effectiveness of FOLFIRINOX (FOL) versus gemcitabine and nab-paclitaxel (GNP) for the first-line treatment of metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2016 ...
Considering taking supplements to treat Postoperative ileus? Below is a list of common natural remedies used to treat or reduce the symptoms of Postoperative ileus. Follow the links to read common ...
CHICAGO (September 10, 2021) — Chewing gum after heart surgery may kickstart the digestive tract, helping patients feel better and potentially be discharged sooner than those who don't use this ...
The potential approval by the FDA of methylnaltrexone and alvimopan will prompt pharmacy and therapeutics committees to evaluate these agents for inclusion in health-system formularies and consider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results